Literature DB >> 25476421

Rapid synthesis of [18F]fluoroestradiol: remarkable advantage of microwaving over conventional heating.

Jianfeng Shi1, George Afari, Sibaprasad Bhattacharyya.   

Abstract

16α-[(18)F]fluoroestradiol ([(18)F]FES) is known as a clinically important tracer in nuclear medicine as an estrogen receptor ligand for investigating primary and metastatic breast cancers. Synthesizing [(18)F]FES is a two-step process associated with [(18)F]fluoride incorporation to the precursor (3-methoxymethyl 16β,17β-epiestriol-O-cyclic sulfone) and subsequent hydrolysis of the [(18)F]fluorinated intermediate with 2 N HCl. The impact of microwave (MW) heating on both fluorination and hydrolysis reactions was investigated. The duration and temperatures of the fluorination reaction were varied for both MW heating and conventional heating (CH) methods. Chemical and radiochemical purity and radiochemical yields were investigated for CH and compared with MW-assisted radiosyntheses. Quality control tests of MW-assisted [(18)F]FES were performed following US Pharmacopeia procedures for clinical-grade positron emission tomography pharmaceuticals. The results demonstrate that microwaving not only improves the (18)F-fluoride incorporation (~55% improvement at 110°C for 4 min) but also significantly reduces hydrolysis time (approximately sevenfold reduction at 120°C) in comparison with CH under similar conditions. The overall isolated radiochemical yield of purified [(18)F]FES was significantly higher (~90% improvement) with MW, and side products were notably fewer. Quality control test results demonstrated that [(18)F]FES produced by microwaving was suitable for human injection.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  F-18; PET; fluoroestradiol; microwave

Mesh:

Substances:

Year:  2014        PMID: 25476421      PMCID: PMC4275410          DOI: 10.1002/jlcr.3248

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  14 in total

1.  The automatic production of 16alpha-[18F]fluoroestradiol using a conventional [18F]FDG module with a disposable cassette system.

Authors:  Seung Jun Oh; Dae Yoon Chi; Christoph Mosdzianowski; Hee Seup Kil; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Appl Radiat Isot       Date:  2006-09-11       Impact factor: 1.513

Review 2.  Targeted functional imaging in breast cancer.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

3.  Microwave-assisted radiosynthesis of [18F]fluorinated fatty acid analogs.

Authors:  Anthony P Belanger; Mukesh K Pandey; Timothy R DeGrado
Journal:  Nucl Med Biol       Date:  2010-12-03       Impact factor: 2.408

Review 4.  Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography.

Authors:  Philip W Miller; Nicholas J Long; Ramon Vilar; Antony D Gee
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.

Authors:  F Dehdashti; F L Flanagan; J E Mortimer; J A Katzenellenbogen; M J Welch; B A Siegel
Journal:  Eur J Nucl Med       Date:  1999-01

6.  Synthesis of 2-[(18)F]Fluoroestradiol, a Potential Diagnostic Imaging Agent for Breast Cancer: Strategies to Achieve Nucleophilic Substitution of an Electron-Rich Aromatic Ring with [(18)F]F(-).

Authors:  Eric D. Hostetler; Stephanie D. Jonson; Michael J. Welch; John A. Katzenellenbogen
Journal:  J Org Chem       Date:  1999-01-08       Impact factor: 4.354

7.  Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.

Authors:  Piyush Kumar; John Mercer; Courtney Doerkson; Katia Tonkin; Alexander J B McEwan
Journal:  J Pharm Pharm Sci       Date:  2007       Impact factor: 2.327

8.  Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.

Authors:  Lanell M Peterson; David A Mankoff; Thomas Lawton; Kevin Yagle; Erin K Schubert; Svetlana Stekhova; Allen Gown; Jeanne M Link; Timothy Tewson; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

9.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.

Authors:  F Dehdashti; J E Mortimer; B A Siegel; L K Griffeth; T J Bonasera; M J Fusselman; D D Detert; P D Cutler; J A Katzenellenbogen; M J Welch
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

10.  Synthesis of Clinical-Grade [(18)F]-Fluoroestradiol as a Surrogate PET Biomarker for the Evaluation of Estrogen Receptor-Targeting Therapeutic Drug.

Authors:  Manish Dixit; Jianfeng Shi; Ling Wei; George Afari; Sibaprasad Bhattacharyya
Journal:  Int J Mol Imaging       Date:  2013-05-09
View more
  3 in total

1.  Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.

Authors:  Frank I Lin; E M Gonzalez; S Kummar; K Do; J Shih; S Adler; K A Kurdziel; A Ton; B Turkbey; P M Jacobs; S Bhattacharyya; A P Chen; J M Collins; J H Doroshow; P L Choyke; M L Lindenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-21       Impact factor: 9.236

Review 2.  PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.

Authors:  John A Katzenellenbogen
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

Review 3.  The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors:  John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2020-02-22       Impact factor: 2.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.